Trial
NCT01266070
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
M.D. Anderson Cancer Center
Collaborators
Novartis
Condition
Von Hippel-Lindau Syndrome
Intervention
Dovitinib
Why stopped
Trial met toxicity stopping rule
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-13